Not provided
Not provided
Not provided
Not provided
difficulty of recruitment
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Neuropathic pain is due to a lesion or disease affecting the nervous system. Antidepressants (ADs) are recommended as the first line treatment. In a murine model, the investigators evidenced that antidepressants antiallodynic action is mediated through β2-adrenergic receptor stimulation and that β-mimetics display the same effect. These data support the idea that β-mimetics could offer a therapeutic alternative to ADs for neuropathic pain treatment. This study will aim at assessing the effects of terbutaline on neuropathic pain symptoms.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| first period with terbutaline and second period with placebo | Other | The studies will be randomized, double-blind, placebo-controlled. It will use a 4 + 4 weeks crossover design for terbutaline vs. placebo (no titration). A washout period (2 weeks) will separate the treatment periods. |
|
| first period with placebo and second period with terbutaline. | Other | The studies will be randomized, double-blind, placebo-controlled. It will use a 4 + 4 weeks crossover design for terbutaline vs. placebo (no titration). A washout period (2 weeks) will separate the treatment periods. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Terbutaline sustained release 5 mg | Drug | Terbutaline 10mg oral per day (5 mg twice a day) during 28 days |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in the average intensity of pain during the last 24 hours reported by the patient on a 11 points Numeric Scale | Day one, day 14 and day 28 of each 4 weeks period |
Not provided
Not provided
Inclusion Criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| André Muller, MD | University Hospital, Strasbourg, France | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Besançon | Besançon | 25030 | France | |||
| Hôpitaux Universitaires de Strasbourg |
Not provided
Not provided
Not provided
Not provided
Not provided
| Strasbourg |
| 67091 |
| France |